BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/11/2026 9:16:12 AM | Browse: 3 | Download: 0
Publication Name World Journal of Hepatology
Manuscript ID 118817
Country Italy
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology
Manuscript Source Invited Manuscript
All Author List Francesco Giangregorio, Elisa Civaschi, Samanta Mazzocchi, Davide Romano, Paolo Clini, Esther Centenara, Umberto Casale and Davide Catucci
Funding Agency and Grant Number
Corresponding Author Francesco Giangregorio, Associate Professor, Chief Physician, Director, Department of Internal Medicine, Val Tidone Hospital, Viale II Giugno 1, Castel San Giovanni 29015, Emilia-Romagna, Italy. f.giangregorio67@gmail.com
Key Words Chronic hepatitis B; Metabolic dysfunction-associated steatotic liver disease; Liver fibrosis; Non-invasive tests; Transforming growth factor-β; L59 (LAP degradation product); Platelet count; Fibrogenesis
Core Tip Non-invasive assessment of liver injury in chronic hepatitis B is evolving beyond static fibrosis markers toward biologically driven models. The L59-based nomogram proposed by Dai et al captures active fibrogenesis through transforming growth factor-βactivation, integrating molecular, inflammatory, and hematologic parameters. This approach is particularly relevant in patients with concurrent metabolic dysfunction-associated steatotic liver disease, where steatosis may be deceptively mild despite advanced fibrosis. A dual, non-invasive evaluation of fibrosis and steatosis is therefore essential to avoid underestimation of disease severity and to optimize risk stratification in dual-etiology liver disease.
Citation Giangregorio F, Civaschi E, Mazzocchi S, Romano D, Clini P, Centenara E, Casale U, Catucci D. Beyond fibrosis: The imperative for dual steatosis and fibrosis assessment in chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease co-pathology. World J Hepatol 2026; In press
Received
2026-01-12 01:47
Peer-Review Started
2026-01-12 01:47
First Decision by Editorial Office Director
2026-01-16 06:48
Return for Revision
2026-01-16 06:48
Revised
2026-01-20 22:10
Publication Fee Transferred
Second Decision by Editor
2026-02-11 02:36
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-02-11 09:16
Articles in Press
2026-02-11 09:16
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com